Search Result

Results for "

Vmat 2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Autophagy (3) Biochemical Assay Reagents (1) Dopamine Receptor (6) Dopamine Transporter (1) Drug Metabolite (3) Environmental Pollutants (1) Fluorescent Dye (1) HDAC (1) Histone Methyltransferase (1) Isotope-Labeled Compounds (2) Monoamine Transporter (31) Nuclear Hormone Receptor 4A/NR4A (1) Reference Standards (4)
By Research Areas:	Cancer (7) Neurological Disease (33)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0480

Reserpine 5+ Cited Publications	Environmental Pollutants Autophagy Monoamine Transporter	Neurological Disease Cancer
Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-16771

Valbenazine 4 Publications Verification NBI-98854	Monoamine Transporter	Neurological Disease
Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the K_i of 110-190 nM .

HY-B0590

Tetrabenazine 1 Publications Verification Ro 1-9569	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0590S

Tetrabenazine-d6 Ro 1-9569-d₆	Monoamine Transporter	Neurological Disease
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-15793

NBI-98782 1 Publications Verification (+)-DTBZ; (+)-α-Dihydrotetrabenazine; (+)-α-DHTBZ	Monoamine Transporter	Neurological Disease
NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a K_i of 3 nM. NBI-98782 has antipsychotic activity .

HY-N0480A

Reserpine hydrochloride 5+ Cited Publications	Monoamine Transporter	Neurological Disease Cancer
Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-19348

Pimelic Diphenylamide 106 5 Publications Verification RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII	HDAC Monoamine Transporter	Neurological Disease Cancer
Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC₅₀ values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing *VMAT2* expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .

HY-B0590A

Tetrabenazine Racemate Ro 1-9569 Racemate	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) Racemate is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine Racemate binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine Racemate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine Racemate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-149170

FFN246	5-HT Receptor Monoamine Transporter	Neurological Disease
FFN246 is a fluorescent, dual substrate of serotonin transporter (SERT) probe and vesicular monoamine transporter 2 (VMAT2) with excitation and emission spectra 392/427 nm. FFN246 can be used for labeling serotonergic neurons in mouse brain tissue through SERT-dependent accumulation .

HY-W677684

Nurr1 agonist 2	Nuclear Hormone Receptor 4A/NR4A	Others
Nurr1 agonist 2 (Compound 7) is a Nurr1 agonist (EC₅₀: 0.07 μM). Nurr1 agonist 2 binds to the recombinant Nurr1 ligand binding domain (LBD) with a K_d value of 0.14 μM. Nurr1 agonist 2 increases the Nurr1-regulated genes tyrosine hydroxylase (TH) and vesicular amino acid transporter 2 (VMAT2) mRNA expression .

HY-110334

FFN 206 dihydrochloride	Fluorescent Dye	Others
FFN 206 dihydrochloride, a fluorescent probe, is used as an excellent Vesicular Monoamine Transporter 2 (VMAT2) substrate with an apparent K_m of 1.16 μM. FFN 206 dihydrochloride is capable of detecting VMAT2 activity in intact cells using fluorescence microscopy, with subcellular localization to VMAT2-expressing acidic compartments without apparent labeling of other organelles .

HY-16771A

Valbenazine tosylate 4 Publications Verification NBI-98854 tosylate	Monoamine Transporter	Neurological Disease
Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the K_i of 110-190 nM .

HY-N0480S

Reserpine-d9	Isotope-Labeled Compounds Monoamine Transporter Autophagy	Neurological Disease Cancer
Reserpine-d₉ is the deuterium labeled Reserpine. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-N0480R

Reserpine (Standard)	Reference Standards Monoamine Transporter Autophagy	Neurological Disease Cancer
Reserpine (Standard) is the analytical standard of Reserpine. This product is intended for research and analytical applications. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-131006

FFN200 dihydrochloride	Monoamine Transporter	Neurological Disease
FFN200 dihydrochloride, a fluorescent substrate of *VMAT2*, selectively trace monoamine exocytosis in both neuronal cell culture and brain tissue. The fluorescence excitation and emission maxima of FFN200 are determined to be 352 and 451 nm, respectively .

HY-B0590B

(+)-Tetrabenazine (+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine	Monoamine Transporter	Cancer
(+)-Tetrabenazine ((+)-TBZ) is the enantiomer of Tetrabenazine (HY-B0590) and is also a Vesicular Monoamine Transporter 2 (VMAT2) inhibitor with a rat K_i of 4.61 nM. (+)-Tetrabenazine inhibits monoamine uptake into granular vesicles of presynaptic neurons. (+)-Tetrabenazine is 3 times more active than (-)-Tetrabenazine. (+)-Tetrabenazine can be used for the research of Huntington's disease and hyperkinetic movement disorders (including chorea) .

HY-G0025

Tetrabenazine Metabolite (-)-β-Dihydrotetrabenazine; (-)-β-HTBZ	Monoamine Transporter Drug Metabolite	Neurological Disease
Tetrabenazine Metabolite is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite is a vesicular monoamine transporter 2 (VMAT2) inhibitor with a high affinity (K_i=13.4 nM) . Tetrabenazine Metabolite is be developed for the treatment of chorea associated with Huntington’s disease and other hyperkinetic disorders .

HY-153472

VMAT2-IN-2 tosylate	Monoamine Transporter	Neurological Disease
VMAT2-IN-2 tosylate is a potent *VMAT2* inhibitor. VMAT2-IN-2 tosylate can be used in research of tardive dyskinesia .

HY-120788

VMAT2-IN-4	Monoamine Transporter	Others
VMAT2-IN-4 (compound 11) is a vesicular monoamine transporter-2 (VMAT2) inhibitor. VMAT2-IN-4 inhibits [ ³H]-DTBZ binding (Ki = 560 nM). VMAT2-IN-4 inhibits [ ³H]-DA (Ki = 45 nM) from entering vesicles and being taken up by cells. VMAT2-IN-4 can be used in methamphetamine addiction research .

HY-161433

VMAT2-IN-3	Monoamine Transporter	Neurological Disease
VMAT2-IN-3 (compound 10) is a potent vesicular monoamine transporter-2 (VMAT2) inhibitor with a K_i of 0.71 nM. VMAT2-IN-3 has the potential for neurological or psychiatric disease research .

HY-W681822

(R,S,S)-Dihydrotetrabenazine R,S,S-DHTBZ	Drug Metabolite Monoamine Transporter	Neurological Disease
(R,S,S)-Dihydrotetrabenazine (R,S,S-DHTBZ) is a kind of discrete isomeric secondary alcohol metabolites of Tetrabenazine (TBZ, HY-B0590), is a poor *VMAT2* inhibitor (K_i = 690 nM) .

HY-B0590D

(-)-Tetrabenazine (-)-TBZ; (3S,11bS)-TBZ; (3S,11bS)-Tetrabenazine	Monoamine Transporter	Neurological Disease
(-)-Tetrabenazine ((-)-TBZ; compound 13) is an enantiomer of Tetrabenazine (HY-B0590). (+)-Tetrabenazine proves 3-fold more active than (-)-Tetrabenazine in inhibiting vesicular monoamine transporter 2 (VMAT2) .

HY-141554

Dihydrotetrabenazine DHTBZ	Monoamine Transporter	Neurological Disease
Dihydrotetrabenazine (DHTBZ) is the active metabolite of Tetrabenazine (HY-B0590). Dihydrotetrabenazine is the inhibitor for human vesicular monoamine transporter 2 (VMAT2), that reduces monoamine content in presynaptic neurons, and can be used in movement disorder research .

HY-158014

JJC8-089	Dopamine Transporter	Neurological Disease
JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .

HY-15793A

Trans (2,3)-Dihydrotetrabenazine (2R,3R,11bR)-rel-Dihydrotetrabenazine; (2R,3R,11bR)-rel-DHTBZ	Drug Metabolite Monoamine Transporter	Neurological Disease
Trans (2,3)-Dihydrotetrabenazine ((2R,3R,11bR)-rel-Dihydrotetrabenazine), a metabolite of Tetrabenazine, shows remarkable inhibition activity on vesicular monoamine transporter (VMAT2) .

HY-117883

GZ-793A	Monoamine Transporter	Neurological Disease
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an K_i of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction .

HY-B0590S1

(+)-Tetrabenazine D6	Monoamine Transporter	Neurological Disease
(+)-Tetrabenazine-d₆ is the deuterium labeled (+)-Tetrabenazine. (+)-Tetrabenazine is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2).

HY-B0590E

Tetrabenazine mesylate Ro 1-9569 mesylate	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) mesylate is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine mesylate binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine mesylate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine mesylate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-118990

Lobelane hydrochloride	Histone Methyltransferase	Neurological Disease
Lobelane hydrochloride is a biologically active compound that has the activity of inhibiting vesicular monoamine transporter-2 (VMAT2). Lobelane hydrochloride has a low affinity for nicotinic acetylcholine receptors (nAChR), thereby enhancing its selectivity for VMAT2. Synthetic structural changes of lobelane hydrochloride have led to some related analogs that show mild changes in affinity for VMAT2. The most potent synthetic lobelane hydrochloride obtained after structural modification has a K(i) value of 630 nM, showing significant VMAT2 selectivity. The biological activity of lobelane hydrochloride suggests that it has the potential to be used in the development of compounds to inhibit methamphetamine abuse .

HY-B0590R

Tetrabenazine (Standard) Ro 1-9569 (Standard)	Reference Standards Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Standard) is the analytical standard of Tetrabenazine (HY-B0590). This product is intended for research and analytical applications. Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0590S3

Tetrabenazine-d7 TBZ-d7-d₇; Ro 1-9569-d₇	Isotope-Labeled Compounds Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-N0480AR

Reserpine hydrochloride (Standard)	Monoamine Transporter Reference Standards	Neurological Disease Cancer
Reserpine (hydrochloride) (Standard) is the analytical standard of Reserpine (hydrochloride). This product is intended for research and analytical applications. Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-16771R

Valbenazine (Standard) NBI-98854 (Standard)	Monoamine Transporter Reference Standards	Neurological Disease
Valbenazine (Standard) is the analytical standard of Valbenazine. This product is intended for research and analytical applications. Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM .

HY-16771B

Valbenazine dihydrochloride NBI-98854 dihydrochloride	Dopamine Receptor	Neurological Disease
Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.

HY-152171

GZ-11608	Monoamine Transporter	Neurological Disease
GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder .

HY-153127

Florbenazine AV-133	Biochemical Assay Reagents	Neurological Disease
Florbenazine (AV-133) is a diagnostic imaging agent targeting the central nervous system monoamine transporter *VMAT2*, and its F-18 labeled form can be used for PET scanning. The biodistribution of [18F]Florbenazine in mice shows a high striatum/cerebellum ratio (0.48), which can be used for the diagnostic research of neurodegenerative diseases (including dementia with Lewy bodies and Parkinson's disease) .

HY-141554A

(2S,3S,11bR)-Dihydrotetrabenazine (2S,3S,11bR)-DHTBZ	Monoamine Transporter	Neurological Disease
(2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a K_i value of 593 nM. (2S,3S,11bR)-Dihydrotetrabenazine inhibits vesicular transport of monoamine neurotransmitters like dopamine and serotonin, reducing their synaptic release. (2S,3S,11bR)-Dihydrotetrabenazine is promising for research of Huntington's chorea and other hyperkinetic disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0480

Reserpine 5+ Cited Publications	Alkaloids Piperidine Alkaloids Structural Classification other families Neurological Disease Classification of Application Fields Anti-aging Plants Disease Research Fields Indole Alkaloids Source Classification Cancer	Environmental Pollutants Autophagy Monoamine Transporter
Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-N0480A

Reserpine hydrochloride 5+ Cited Publications	Rauvolfia verticillata (Lour.) Baill. Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Source Classification	Monoamine Transporter
Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-N0480R

Reserpine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification other families Plants Indole Alkaloids Source Classification	Reference Standards Monoamine Transporter Autophagy
Reserpine (Standard) is the analytical standard of Reserpine. This product is intended for research and analytical applications. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-N0480AR

Reserpine hydrochloride (Standard)	Rauvolfia verticillata (Lour.) Baill. Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Source Classification	Monoamine Transporter Reference Standards
Reserpine (hydrochloride) (Standard) is the analytical standard of Reserpine (hydrochloride). This product is intended for research and analytical applications. Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

Cat. No.	Product Name	Chemical Structure

HY-B0590S

Tetrabenazine-d6
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active *VMAT2*-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds *VMAT2* to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

Tetrabenazine-d6

Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-N0480S

Reserpine-d9
Reserpine-d₉ is the deuterium labeled Reserpine. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

HY-B0590S1

(+)-Tetrabenazine D6
(+)-Tetrabenazine-d₆ is the deuterium labeled (+)-Tetrabenazine. (+)-Tetrabenazine is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2).

HY-B0590S3

Tetrabenazine-d7

Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

Host:	Mouse (2)
Reactivity:	Human (2) Rat (2) Mouse (2)
Application:	IHC-P (2) ICC/IF (2) FC (2)
Isotype:	IgG1 (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88094

	*SLC18A2 (VMAT2) Antibody (YA7778)* SVAT; SVMT; VAT2; Vmat2	IHC-P, ICC/IF, FC	Human, Mouse, Rat
	SLC18A2 (VMAT2) Antibody (YA7778) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SLC18A2 (VMAT2).

HY-P88094A

	*SLC18A2 (VMAT2) Antibody (YA7778)(PBS only)* SVAT; SVMT; VAT2; Vmat2	IHC-P, ICC/IF, FC	Human, Mouse, Rat
	SLC18A2 (VMAT2) Antibody (YA7778) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SLC18A2 (VMAT2).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks